The global cell therapy market size is estimated to be at a remarkable CAGR of 31.7% from 2023 to 2028. The market size is predicted to grow to USD 55.90 billion by 2028 from USD 14.08 billion in 2023. Cell therapies have a lot of advancement in treating a variety of diseases. Many trials are underway in the race among countries and companies to develop effective COVID-19 vaccines and therapeutics. To ensure the safety and effectiveness of stem cell therapy, the researcher must perform clinical trials. Understanding the nature of stem cells is a long way from using them therapeutically. There are many hopes for cell therapy for human diseases, but there are still many issues to work out. Nevertheless, there is optimism that cell therapy will be approved to treat viral diseases like COVID-19 in the future; it will boost the cell therapy market in the forecast period.
Cell therapy is the transfer of intact, live cells or curing a disease into a patient to help lessen the disease. The cells can come from the patient (autologous cells) or a donor (allogeneic cells). In cell therapy, the cells' ability to convert into various cell types can be categorized. Pluripotent cells can convert into any cell type in the body, while multipotent cells can transform into other types with a smaller range than pluripotent cells. The treatment determines the type of cells used. It helps replace missing or diseased cells in a patient's body with new, healthy ones.
Continuous growing regulatory approval of cell therapy products for various disorders is expected to drive growth for the global market.
Adult aggressive B-cell lymphomas (Yescarta and Kymriah), young adults (Kymriah), and B-cell leukemia in children, most recently, relapsed or refractory mantle cell lymphoma (MCL) in adults have all been authorized by the FDA (Tecartus). Swedish Cancer Institute is pleased to provide Chimeric Antigen Receptor (CAR)-T cell therapy to eligible patients. CAR-T cell therapy is a relatively new form of immunotherapy that has resulted in widespread patient remission since its approval in 2017. Insurance firms are also developing plans for FDA-approved treatments, including CAR-T cell therapy, although it was only recently approved for use in April 2017.
Increased application of human cells in cell therapy research, technical advances in cell therapy, and the rising of Preclinical and clinical trials of cell therapy for various lung disorders.
In addition to cancer and cardiovascular disease, lung diseases are a leading cause of morbidity and death globally. There are curative treatments and no safe options for specific disease conditions. Because of their anti-fibrotic effects and intrinsic anti-inflammatory, cell therapies represent a novel therapeutic approach. The mesenchymal stem/stromal cells (MSC) are the most researched cell product for various diseases. MSCs are a promising therapeutic method for treating lung diseases in preclinical & clinical trials. About 350 clinical trials using mesenchymal cells are currently in progress worldwide. Several studies focus on rheumatology (osteoarthritis, rheumatoid arthritis), cardiology (stroke, myocardial infarction, ischemia of the lower limbs), muscle degeneration (myopathy), diabetes, graft rejection, autoimmune disease (lupus), and other chronic disorders.
Regenerative medicine's growth is expected to boost the global cell therapy market rapidly.
Regenerative treatments, including gene and cellular therapies, stimulate cell, tissue, and organ regeneration and restore function. For example, human embryonic stem cells differentiated into retinal cells are used to treat differentiated into retinal pigment epithelial cells, and AMD is used to treat Stargardt's disease by a U.S. biotech company (Ocata Therapeutics). Phase I and II trials are ongoing in both cases to assess the therapeutic efficacy and approach's safety. The initial findings are encouraging but modest. The London Project is designing another AMD trial to Cure Blindness in collaboration with a pharmaceutical firm (Pfizer). Seeding cells onto biomimetic or natural scaffolds produces bioartificial tissues (tissue engineering).
The rising prevalence of chronic diseases such as cancer and cardiac disorders is predicted to accelerate the growth rate of the global cell therapy market.
According to WHO, Cancer is one of the world's leading causes of death, with about 9.6 million deaths in 2018. Africa, Asia, and Central and South America account for more than 60% of all new cases worldwide each year. Seventy percent of all cancer deaths occur in these areas. Lung, colorectal, stomach, liver, and breast cancers account for most cancer deaths yearly. Cancer is the leading cause of death worldwide, with almost 10 million deaths expected by 2020. Cardiovascular diseases (CVDs) are the leading cause of death worldwide, claiming the lives of around 17.9 million people annually. Representing 31% of all deaths worldwide, and Heart attacks & strokes account for 85% of these deaths.
Furthermore, the global cell therapy industry is driven by rising government initiatives to raise awareness of cell therapy in healthcare facilities in developed countries and encourage cancer-cell therapy research and the world's growing senior population.
The availability of sufficient cells for transplantation into a patient is a problem for this therapy. This is due to the difficulty of obtaining specialized cells from the human body, such as brain cells. Furthermore, since specialized cells can generate sufficient numbers of cells for specific cell therapies, having a limited ability to replicate can be challenging. Costly treatment, poorly designed reimbursement programs, and difficulties associated with the CAR-T cell logistical and production process challenges faced by healthcare organizations are impeding the development of the market. As the American Cancer Society reported, some people have had severe side effects due to this procedure, particularly as the CAR T cells multiply in the body to fight cancer. Another issue is that some healthy B cells that help fight infection would be destroyed by the cells, placing the patient at risk of infection. In the healthcare sector, there is a shortage of professionals and staff. Restriction of regulatory approval of the cell therapy product.
Impact of COVID-19 on the global cell therapy market:
COVID-19 is spreading rapidly across the world. The COVID-19 pandemic is affecting the availability of necessary routine healthcare facilities and treatments, such as Cell therapies and CAR-T therapy, a life-saving treatment option for patients. Cell therapies have many potentials for treating various diseases, but their commercial viability has been questioned for a long time. As the world struggled with an unprecedented global pandemic, it spoke with a few organizations that are either already CAR-T certified or have recently begun the process to assess COVID-19's effect on CAR-Ts. Not only for today's CAR-Ts, but also for the next wave of cell therapies, the improvements caused by the pandemic may have long-term consequences.
Also, suppliers struggle to ensure access to treatments for patients and raw materials. The already complicated cell therapy supply chain and manufacturing process have impacted negatively in a pandemic. COVID-19 has impacted cell therapy in various ways in the short term, are Clinical experiments are taking a break for the time being. In specific centers, the use of CAR-T cells has decreased. Delays for facilities that have not yet been approved, as well as a renewed emphasis on telemedicine and outpatient monitoring for hospitals that began the phase before COVID-19.
Market Size Available
2022 to 2028
2023 to 2028
By Technology, Type, Cell Source, Application, End-Users, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
This research report on the global cell therapy market has been segmented and sub-segmented based on technology, type, cell source, application, end-users, and region.
Cell Therapy Market - By Technology:
Somatic Cell Technology
Cell Immortalization Technology
Viral Vector Technology
Genome Editing Technology
Cell Plasticity Technology
The somatic cell technology market leads with the dominant shares of the market, where the cell immortalization technology segment has been growing faster over the past few years. Rising investments in the development of new techniques in healthcare with random technologies are a major factor for the segments to grow tremendously.
Cell Therapy Market - By Type:
The autologous segment is anticipated to rule the market shares in the forecast period. Rising incidences of chronic diseases and an increasing elderly population are fuelling the segment's demand to an extent.
Cell Therapy Market - By Cell Source:
Umbilical Cord Blood-Derived Cells
Neural Stem Cell
The umbilical cord blood-derived cells segment is gaining traction over the market shares with the increasing awareness of the benefits of this procedure.
Cell Therapy Market – By Application:
Wounds & Injuries
The cardiovascular segment is growing at a higher rate and is expected to have significant growth opportunities in the coming years. On the other hand, the oncology application sector will likely have the dominant market share in the forecast period due to the rising number of cancer patients worldwide.
Cell Therapy Market – By End-User:
Hospitals & Clinics
Regenerative Medicine Centres
Diagnostic & Research Centres
The hospitals and clinics segment is leading with the most significant shares of the market. The rising number of hospitals and the increasing patient pool is ascribed to bolster the demand of this segment.
Cell Therapy Market – By Region:
Rest of North America
Rest of Europe
Rest of APAC
Rest of Latin America
Geographically, the North American cell therapy market held the largest regional market share in the global cell therapy market in 2020 and accounted for a market share of 52.7%. Rising healthcare costs and increased CVD incidence primarily drive this regional market. Over the forecast period, the United States has contributed most to the North American regional market. The market is growing as people's disposable income rises and their awareness of healthcare increases. On the other hand, the Canadian market is anticipated to be the largest in the coming years.
The European market was the second-largest regional market in the global market in 2020. The growing number of clinical studies for cell-based therapies is accelerating market growth. The United Kingdom is expected to dominate the European regional market. Growing research and development activities and adopting advanced cell-based therapies are expected to contribute to the largest market share in this region.
In 2020, the APAC region was one of the fastest-growing regions in the cell therapy market. By 2025, the market is expected to have a market share of USD 4.01 billion, with a CAGR of 12.6 percent over the forecast period. As a result of the number of pharmaceutical and biotechnology industries in the APAC region, China has dominated the largest market share. On the other hand, technological advancements and increasing disposable income are most likely to augment the Cell therapy market. On the other hand, Japan is anticipated to grow with an increasing CAGR. Furthermore, the Indian cell-based therapy market is projected to witness a healthy market share during the forecast period. Favorable reimbursement programs, improving healthcare infrastructure, and government investments encourage regional market growth.
Over the forecast period, Middle East Africa is expected to have a moderate share. Factors such as a significant increase in the number of centers and institutes engaged in stem cell therapy research and innovation and rising healthcare awareness are likely to fuel market growth.
KEY MARKET PARTICIPANTS:
Some of the promising companies dominating the global cell therapy market profiled in this report are Merck KGaA and Thermo Fisher Scientific Inc, Lonza Group, Osiris Therapeutics, Inc., Danaher Corporation, Becton, Dickinson and Company, Sartorius AG, Fresenius Medical Care AG & Co. KGaA, FUJIFILM Irvine Scientific, Corning Incorporated, Mesoblast Ltd., Medipost Co., Ltd. Avantor, Inc., CellGenix GmbH, Bio-Techne Corporation, STEMCELL Technologies, SIRION Biotech GmbH, and Hemasoft.
As per our research report, the global cell therapy market size is forecasted to grow to USD 55.90 billion by 2028.
Based on technology, the somatic cell technology segment led the cell therapy market in 2022.
Based on the cell source, the umbilical cord blood-derived cells segment is forecasted to register dominance among all from 2023 to 2028.
Merck KGaA and Thermo Fisher Scientific Inc, Lonza Group, Osiris Therapeutics, Inc., Danaher Corporation, Becton, Dickinson and Company, Sartorius AG, Fresenius Medical Care AG & Co. KGaA, FUJIFILM Irvine Scientific, Corning Incorporated, Mesoblast Ltd., Medipost Co., Ltd. Avantor, Inc., CellGenix GmbH, Bio-Techne Corporation, STEMCELL Technologies, SIRION Biotech GmbH, and Hemasoft are a few of the noteworthy companies operating in the global cell therapy market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com